Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsCORT +2.61%85 Pretax Margin % is 17.93% as of Jun. 2026, which is 42% below its 10-year median of 31.04. GuruFocus rates CORT with a GF Score™ of 85/100 and a GF Value™ of $68.28 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 945 Biotechnology companies, Corcept Therapeutics ranks better than 73.65% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Corcept Therapeutics Pretax Margin % Related Terms
Corcept Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CORT vs APGE, KRYS, NUVL: Pretax Margin % Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (CORT) has a Pretax Margin % of 17.93% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Corcept Therapeutics and its competitors. This is 42% below median its historical median of 31.04. Over the past decade, Corcept Therapeutics' Pretax Margin % has ranged from 3.17 to 38.07. According to the industry distribution chart, Corcept Therapeutics ranks #249 out of 945 companies in the Biotechnology industry, placing it in the top 26.3%.
Is Corcept Therapeutics' Pretax Margin % too high?
Corcept Therapeutics' current Pretax Margin % of 17.93% is 42% below median its 10-year median of 31.04. Over the past 10 years, this metric has ranged from a low of 3.17 to a high of 38.07. Based on the distribution chart, Corcept Therapeutics ranks #249 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Pretax Margin % compare to APGE and KRYS?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #249 out of 945 companies for Pretax Margin %. This puts Corcept Therapeutics in the upper half of its industry. Historically, Corcept Therapeutics' own Pretax Margin % has ranged from 3.17 to 38.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Pretax Margin % is 17.93%, which is 42% below median its own 10-year median of 31.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $68.28, compared to a current price of $110.77 — trading 62.2% above its estimated fair value. The current Pretax Margin % is 17.93%, which is 42% below median its 10-year median of 31.04. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Pretax Margin % is 17.93% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (CORT) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of $110.77 is trading 62.2% above its estimated GF Value™ of $68.28.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for CORT:
Pretax Margin %: 17.93% (42% below median its 10-year median of 31.04)
GF Value™: $68.28 vs. price of $110.77 (62.2% above fair value)
No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for CORT
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORT has been successfully added to your 
